ReviewBlood and lymphatic cancer : targets and therapy2017
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma.
Divaya Bhutani et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it